Obesity and CHD
This article was originally published in The Tan Sheet
Executive Summary
Even without additional risk factors, obesity in young adulthood and middle-age carries an increased risk of hospitalization or death from coronary heart disease, cardiovascular disease or diabetes in older age compared to normal weight individuals, a study in the Jan. 11 Journal of the American Medical Association finds. For instance, the risk of death from CHD was 43% higher for obese individuals in the low-risk group compared to normal weight individuals at the same risk level, according to Lijing Yan, PhD, Feinberg School of Medicine, Northwestern University, et al. The findings, which were gleaned from a multivariable analysis of 17,643 participants in the Chicago Heart Association Detection Project, have "significant public health implications," the authors conclude. GlaxoSmithKline's switch application for the anti-obesity drug Xenical (orlistat) will be reviewed by two FDA advisory committees Jan. 23 (1"The Tan Sheet" Jan. 2, 2006, p. 3)...
You may also be interested in...
Xenical Short-Term Switch Odds Slimmer Than Long-Term – Experts
Xenical's long-term prospect for switch appears promising, but its chances of being recommended for OTC sale by an upcoming advisory panel are slim, some switch experts say
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.